ATXS
Astria Therapeutics, Inc. (ATXS) Management Analysis (2026)
Overall Score
Leadership Governance
Management appears financially conservative with very low debt-to-equity (0.02) and debt-to-assets (0.02), reducing balance-sheet risk.
However, the company is still deeply unprofitable with negative ROE (-0.38) and ROIC (-0.43), indicating management has not yet translated capital into returns.
No recent news indicates a material change in leadership, governance, or strategic direction.
Execution Operating Performance
Operating performance remains weak, with negative operating margin (-151.4%) and negative EBITDA margin (-139.4%).
Cash generation is still negative, as operating cash flow per share (-1.76) and free cash flow per share (-1.78) remain below zero.
The company’s extremely high R&D-to-revenue (110.3%) and SG&A-to-revenue (42.1%) suggest heavy spending relative to current revenue scale.
Capital Allocation Financial Discipline
Capital structure remains disciplined, with current ratio at 10.78 and cash ratio at 4.09, indicating ample liquidity.
Debt remains minimal relative to capital and market value, which limits near-term financing risk.
Despite liquidity strength, the company is still burning cash, so capital allocation effectiveness remains unproven.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Astria Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

